Research Activity
LB Pharma’s Novel Antipsychotic LB-102 Shows Promise in Phase II Schizophrenia Trial
LB-102, Benzamide antipsychotic, Schizophrenia treatment, Phase II clinical trial, PANSS score reduction, First-in-class potential
LB Pharma’s Phase II Success Revives Promising Antipsychotic Class for US Patients with Schizophrenia
LB-102, schizophrenia, Phase II trial, antipsychotic, benzamide class
LB Pharma’s Novel Antipsychotic LB-102 Shows Promising Phase II Results for Schizophrenia
LB-102, schizophrenia, antipsychotic, Phase II trial, benzamide class
LB Pharma’s Phase II Success Revitalizes Benzamide Antipsychotics for US Schizophrenia Treatment
LB-102, schizophrenia, benzamide antipsychotics, Phase II trial, efficacy, safety
LB Pharma’s Novel Antipsychotic LB-102 Shows Promising Phase II Results for Schizophrenia
Schizophrenia treatment, Antipsychotic drugs, Clinical trial results, Benzamide class, LB-102
Novo Nordisk and Variant Bio Collaborate on Metabolic Disease Research, Focusing on Diverse Populations
Novo Nordisk, Variant Bio, Metabolic disease, Genetic research, Diverse populations, VB-Inference platform, Benefit-sharing program
Metsera Advances with Positive Phase IIa Results for Monthly GLP-1RA Dosing
Metsera, GLP-1RA, MET-097i, obesity treatment, monthly dosing, weight loss, clinical trials
XyloCor Therapeutics Secures $67.5 Million in Series B Funding to Advance Cardiovascular Gene Therapy
XyloCor Therapeutics, Series B funding, cardiovascular gene therapy, XC001, refractory angina, CABG, clinical trials
Immuneering’s Pancreatic Cancer Therapy Shows Promising Results in Phase 2a Trial, Stock Surges 55%
Immuneering, IMM-1-104, Pancreatic Cancer, Phase 2a Trial, MEK Inhibitor, Cancer Therapy, Clinical Trial Results, Stock Surge
Pfizer and PostEra Expand AI-Driven Drug Discovery Partnership to Include Antibody-Drug Conjugates (ADCs)
AI-driven drug discovery, Antibody-Drug Conjugates (ADCs), Pfizer, PostEra, AI Lab, Proton platform, small molecule therapeutics, medicinal chemistry.